AdaptHealth (AHCO) Q2 2026 Earnings Call Transcript
AdaptHealth (AHCO) reported Q2 2026 net revenue of $740.3 million, up 12.7% year over year, with organic revenue growth of 15.9%. Adjusted EBITDA was $132 million, down 3.2%, and full-year revenue guidance was cut to $2.85-$2.89 billion with adjusted EBITDA of $490-$520 million. The company cited West Coast contract costs and a $30 million supplier price headwind, plus a $235 million diabetes divestiture.
How this was made
The 30-second read
Why it matters
The key trading signal is the downward revision to full-year adjusted EBITDA guidance, driven by higher West Coast contract costs and an immediate manufacturer price increase effective July 1, alongside negative free cash flow and leverage.
Market read
Investors get a concrete guidance reset for 2026 profitability and cash flow, plus quantified headwinds tied to contract costs and supplier pricing, which can drive revaluation of the stock’s margin outlook.
What to watch
The call cites a government-imposed DME moratorium and potential expiration by Aug. 24, which could change the fee-for-service opportunity set and reduce perceived downside if lifted.
Background
AdaptHealth reported Q2 2026 results and discussed portfolio pruning after selling its diabetes business, alongside operational issues in a large West Coast capitated contract.
Ticker impact
AdaptHealth guided full-year adjusted EBITDA down to $490M-$520M after elevated West Coast contract costs and a $30M profit headwind from a July 1 manufacturer price increase.
Likely negative-to-neutral near-term as investors weigh lower EBITDA guidance and negative FCF against revenue growth and restructuring savings.
The article provides specific, time-relevant guidance revisions (EBITDA and revenue excluding discontinued diabetes), cost headwinds (contract costs, supplier price increase), and liquidity/capital structure details (negative FCF, leverage 3.06x, $325M debt redemption).
Market effects
Highlights execution and pricing risk in home medical equipment and capitated sleep/respiratory resupply models, potentially affecting sentiment toward similar DME-capitated operators.
West Coast operational inefficiencies and a DME moratorium limiting fee-for-service expansion are emphasized as a regional constraint.
Limited direct global relevance; primarily a US healthcare services and DME execution story.
Counterpoint
Revenue growth and a large diabetes divestiture could improve segment focus, and restructuring savings plus digitization (AI mask fitting) may offset some margin pressure over time.
Key entities
- companyAdaptHealth Corp.
Subject of the earnings call transcript, providing Q2 results and revised 2026 guidance.
- executiveSuzanne Foster
CEO who attributed margin pressure to inherited workflow inefficiencies and the supplier price increase.
- executiveJason Clemens
CFO who discussed cost actions, leverage, and cash flow guidance.
